Shih-Wen Lin

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Smoking Cessation

Diffuse Large B Cell Lymphoma

Top Venues

PharmacoEconomics

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim, Matthew Matasar
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics 42 (5) (2024)
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim, Matthew Matasar
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics 42 (5) (2024)
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim, Matthew Matasar
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics 42 (5) (2024)
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim, Matthew Matasar
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics (2024)
Matthew Matasar, Javier Sanchez Alvarez, Helene Parise, Eric Zuk, Danilo Di Maio, Sheila Shapouri, Eunice Kim, Shih-Wen Lin
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics 27 (1) (2024)
Shih-Wen Lin, Sheila Shapouri, Hélène Parisé, Eric Bercaw, Mei Wu, Eunice Kim, Matthew Matasar
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics 42 (5) (2024)
Matthew Matasar, Javier Sanchez Alvarez, Helene Parise, Eric Zuk, Danilo Di Maio, Sheila Shapouri, Eunice Kim, Shih-Wen Lin
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics (2024)